Atai Life Sciences N.V. (ATAI)
Automate Your Wheel Strategy on ATAI
With Tiblio's Option Bot, you can configure your own wheel strategy including ATAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATAI
- Rev/Share 0.0106
- Book/Share 0.8639
- PB 2.6084
- Debt/Equity 0.0937
- CurrentRatio 4.0693
- ROIC -0.5524
- MktCap 451694250.0
- FreeCF/Share -0.4413
- PFCF -5.8062
- PE -2.662
- Debt/Assets 0.0727
- DivYield 0
- ROE -1.024
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Read More
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
Published: June 23, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathways (NASDAQ:CMPS)' late-stage trial of its synthetic psilocybin COMP360 in treatment-resistant depression (TRD). Compass Pathways on Monday reported that its COMP360 therapy reached its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo.
Read More
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Read More
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Read More
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
Read More
atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the combined entity will provide investors with maximum exposure to a promising therapy targeting treatment-resistant depression (TRD), analysts at Jefferies believe. BPL-003, Beckley's intranasal formulation of 5-MeO-DMT, is a short-acting psychedelic with the potential to deliver rapid and durable effects in TRD.
Read More
atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
Read More
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced a definitive agreement under which atai and Beckley plan to combine in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase 2b success criteria.
Read More
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Read More
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.
Read More
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Read More
atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytech's depression therapy
Published: May 20, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positive clinical trial results from Beckley Psytech's BPL-003 program targeting treatment-resistant depression (TRD). Beckley Psytech's Phase 2a study of BPL-003, an intranasal form of 5-MeO-DMT, showed that a single dose of the therapy along with selective serotonin reuptake inhibitor (SSRI) therapies, produced rapid, robust, and sustained antidepressant effects.
Read More
atai Life Sciences shares gain momentum ahead of pivotal trial readouts
Published: May 15, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the company's first quarter results. The analysts repeated their ‘Buy' rating and $5 price target on atai, which traded up 11.8% at $1.60 on Thursday afternoon.
Read More
atai Life Sciences doses first patient in Phase 2 social anxiety trial
Published: May 13, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.
Read More
atai Life Sciences doses first patient in Phase 2 social anxiety trial
Published: May 13, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.
Read More
Insiders Make Huge Purchases of These 4 Biotech Stocks
Published: March 26, 2025 by: 24/7 Wall Street
Sentiment: Neutral
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Read More
atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026
Published: March 18, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update. “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
Read More
atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway
Published: March 17, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dosed its first patient in the Phase 2 Elumina trial for VLS-01, a buccal film formulation of DMT designed to treat treatment-resistant depression.
Read More
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial
Published: March 11, 2025 by: Proactive Investors
Sentiment: Positive
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression. Topline results are expected from the first treatment phase of the trial in the first quarter of 2026.
Read More
Atai: Following The Path That Spravato Laid And Moving Beyond It
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.
Read More
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of $2.10 per share, and the closing of the underwriter's option to purchase 3,928,571 additional common shares occurred on February 19, 2025. The aggregate gross proceeds from …
Read More
atai Life Sciences announces pricing of $55M public offering of shares
Published: February 13, 2025 by: Proactive Investors
Sentiment: Negative
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwriter has a 30-day option to purchase up to an additional approximately 3.9 million shares.
Read More
atai Life Sciences Announces Pricing of Public Offering of Common Shares
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai.
Read More
atai Life Sciences Announces Proposed Public Offering of Common Shares
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai.
Read More
About Atai Life Sciences N.V. (ATAI)
- IPO Date 2021-06-18
- Website https://www.atai.life
- Industry Biotechnology
- CEO Srinivas G. Rao
- Employees 54